Back Funds overview

Candriam | Candriam Oncology Impact Acc

The fund will invest in shares of companies operating in the field of oncology (study, diagnosis, treatment, etc. of cancer) whose registered offices and/or principal activities are in the whole world. The fund seeks to achieve capital growth by investing in the principal assets traded, outperform the benchmark index and thus have a positive social long term impact, by selecting companies that take on certain societal challenges and that deploy resources in the fight against cancer.
Quote
Quote
€272,21
Quote date
01-04-2026
Performance in EUR
Date
01-04-2026
This year
-0,43%
1 week
1,85%
1 month
-3,20%
3 months
-0,43%
6 months
15,73%
1 year
17,79%
3 years (annualised)
4,88%
5 years (annualised)
3,67%
Since start (annualised)
8,70%
Indicators
Standard deviation (3yr)
16,00%
Share ratio (3yr)
0,19
Beta (3yr)
1,13
Alpha (3yr)
1,66
Tracking error (3yr)
7,06
Top 10 holdings (30-09-2025)
Eli Lilly and Co
6,34 %
AstraZeneca PLC
4,11 %
Roche Holding AG
3,94 %
Novartis AG Registered Shares
3,79 %
Amgen Inc
3,05 %
Danaher Corp
3,02 %
Intuitive Surgical Inc
2,87 %
Pfizer Inc
2,79 %
Gilead Sciences Inc
2,65 %
Thermo Fisher Scientific Inc
2,58 %
Fees
Entry fee
-->Tarievenkaart / Cost information sheet
Exit charges
-->Tarievenkaart / Cost information sheet
Estimated ongoing charges
1,11%
Dividend
Dividend paying
No
Characteristic
Asset Manager
Candriam
Asset class
Equities
Investment category
Equities - Global
Active/Passive
Active
Fund code
205143
Fund code fractional orders
-
Fund manager name
Linden Thomson|Servaas Michielssens
ISIN
LU1864483166
Sustainable Classification
Art. 9, impact investing
Sustainability Rating
Domicile
Luxembourg
Currency
EUR
Fund size (mio)
1.406,88 (01-04-2026)
Cut-off time
-
Execution date
-
Inception date
20-02-2019
Benchmark
MSCI World NR USD
Minimum investment amount
-
Assortiment
Self Directed Investing Plus, Investment advice